The Role of Anticoagulation in COVID-19-Induced Hypercoagulability.
Curr Cardiol Rep
; 22(7): 53, 2020 06 17.
Article
em En
| MEDLINE
| ID: mdl-32556892
ABSTRACT
PURPOSE OF REVIEW We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. RECENT FINDINGS:
The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Estado Terminal
/
Trombofilia
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article